buyWeak
Randy Milby bought $9,752 of CNTN
CEO at Tharimmune, Inc.. 4,600 shares at an average of $2.12, traded Dec 19, 2024, filed Dec 20, 2024.
Conviction score
31Value
$9,752
4,600 shares
Holdings after
17,534
+36% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- 0Trade size$10k at market
- +6Relative to holdingsHoldings up 36%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001493152-24-051134, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 19, 2024 | POpen-market purchase Common Stock | +4,600 | $2.12 | $9,752 | 17,534 | Dec 20, 2024 |
Related signals
Other insiders at Tharimmune, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | CNTNsell Tharimmune, Inc. | Gary S. Stetz director | $344k 100,351 shares | -43% | |
| 67Notable | Tharimmune, Inc. | Sireesh Appajosyula Chief Executive Officer | $91k 61,496 shares | +1824% | |
| 71Notable | Tharimmune, Inc. | Gravitas Capital LP Executive Chairman | $500k 337,838 shares | +86% | |
| 53Moderate | Tharimmune, Inc. | Sanam Parikh COO | $1,450 1,000 shares | +130% | |
| 31Weak | CNTNbuy Tharimmune, Inc. | Sanam Parikh COO | $1,001 770 shares | - | |
| 30Weak | CNTNbuy Tharimmune, Inc. | Sireesh Appajosyula Chief Operating Officer | $10k 5,000 shares | +87% | |
| 44Moderate | CNTNbuy Tharimmune, Inc. | Randy Milby CEO | $15k 29,000 shares | +23% | |
| 46Moderate | CNTNbuy Tharimmune, Inc. | Randy Milby CEO | $10k 10,000 shares | +9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.